Clinical trialNCT00446342CompletedPhase 1Interventional

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

SponsorSunesis PharmaceuticalsEnrollment21B-lymphoid MalignanciesChronic Lymphocytic LeukemiaMantle Cell LymphomaMultiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Glenn Michelson, MD
Sunesis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Stanford Cancer Center
Stanford, California, United States
Winship Cancer Institute at Emory University
Atlanta, Georgia, United States
Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, United States
Hackensack University Medical Center at the Cancer Center
Hackensack, New Jersey, United States
Md Anderson Cancer Center, University of Texas
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SNS-032

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Feb 2007
Primary completion: 31 Dec 2008
Completion: 31 Mar 2009
Last update posted: 11 Apr 2017
Registered enrollment: 21
Registry id: NCT00446342

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.